Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 81.38

+4.5%

Jan 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2588)	9/17/2009 3:43:11 PM
From: Jibacoa	of 3722

XNPT Opened with a good UG today and traded above its June 30 H of $23.90 The stock is still up 26.55% on volume > 2.043.600 > 9x its ADV bigcharts.marketwatch.com It announced today top-line results from a PIIb evaluating the safety and efficacy of GSK1838262/XP13512 for neuropathic pain associated with post-herpetic neuralgia. The 14-week, double-blind, placebo-controlled study enrolled 376 subjects with PHN who had been experiencing pain for at least three months. The drug was generally well tolerated at all doses in the study.(GSK is the one doing the trial.) XNPT has no significant LTD. In June was when it announced positive results of its PII of arbaclofen placarbil in patients with spasticity following spinal cord injury. The stock is not completely off from its longer term DT, but with some good news it could get to test its Dec H at $31.82 and with a better market environment (like the DOW pushing through the 'Maginot Line' with good volume <g>), it could get to test its Oct H at $49.16 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next